IP Verse

Cellectis opposition analysis

COMPANY ANALYSIS

Latest patents of Cellectis opposed by its competitors

Patent:
EP2997141
Grant Date:
Oct 12, 2022
Title:
Cd19 Specific Chimeric Antigen Receptor And Uses Thereof
Oppositions:
1
Patent:
EP3116902
Grant Date:
Jan 1, 2020
Title:
Method For Generating T-Cells Compatible For Allogenic Transplantation
Oppositions:
4
Patent:
EP3189073
Grant Date:
Dec 25, 2019
Title:
Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer Immunotherapy
Oppositions:
1
Patent:
EP3126390
Grant Date:
Oct 16, 2019
Title:
Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy
Oppositions:
1
Patent:
EP3008186
Grant Date:
Nov 28, 2018
Title:
Methods For Non-Transgenic Genome Editing In Plants
Oppositions:
4
Patent:
EP3105317
Grant Date:
Sep 19, 2018
Title:
Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells
Oppositions:
2
Patent:
EP3004349
Grant Date:
Mar 28, 2018
Title:
A Method For Producing Precise Dna Cleavage Using Cas9 Nickase Activity
Oppositions:
1
Patent:
EP3004337
Grant Date:
Aug 2, 2017
Title:
Methods For Engineering T Cells For Immunotherapy By Using Rna-Guided Cas Nuclease System
Oppositions:
1

Competitors of Cellectis

JAMES POOLE LIMITED

ACOPAT

ADEXE S.R.L.

Want to track Cellectis?

Feel free to send us a message here and we will get back to you